Two College leaders — Todd Mahr, MD, FACAAI, Executive Medical Director, and J. Allen Meadows, MD, FACAAI, Executive Director of Advocacy and Government Affairs — attended the US Food and Drug Administration’s (FDA) annual Compounding Listening Session on Friday, May 17.
Allergy immunotherapy has been a major focus of this meeting in the past. This year’s drug compounding listening and informational sessions focused on: guidance and policy updates; compounding with bulk drug substances; drug shortages; compounded epinephrine; compounding incidents; FDA’s Compounding Quality Center of Excellence; IV hydration clinics; and more. Some topics were more relevant to allergy than others. Stakeholders had the opportunity to give their perspectives on any topics related to compounding. After attending the meeting, College leaders do not anticipate changes in FDA rules governing mixing of allergy extracts in 2024.
